Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.38 |
| ▸ | SMPD1 | P17405 | 5/20 | 0.38 |
| ▸ | FDPS | P14324 | 9/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.35 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14778378 | 1.00 | TSHR (0.42) | TSHRTHRBGGPS1SMPD1FDPS | |
| SCHEMBL3249837 | 1.00 | TSHR (0.42) | TSHRTHRBGGPS1SMPD1FDPS | |
| SCHEMBL14778439 | 1.00 | TSHR (0.42) | TSHRTHRBGGPS1SMPD1FDPS | |
| SCHEMBL14778077 | 1.00 | TSHR (0.42) | TSHRTHRBGGPS1SMPD1FDPS | |
| SCHEMBL2573007 | 1.00 | TSHR (0.42) | TSHRTHRBGGPS1SMPD1FDPS | |
| SCHEMBL4451444 | 0.97 | TSHR (0.37) | TSHRTHRBGGPS1SMPD1FDPS | |
| SCHEMBL6160701 | 0.89 | TSHR (0.36) | TSHRTHRBFDPS | |
| Hydrochloric Acid SCHEMBL9418676 | 0.84 | HTT (0.56) | — | |
| Methyl Nonyl Ketone SCHEMBL21328499 | 0.82 | CES1 (0.42) | TSHRCES2 | |
| SCHEMBL95578 | 0.79 | TSHR (0.46) | TSHRTHRBGGPS1SMPD1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237536-A1 | Treating or Preventing Pain Using Spicamycin Derivatives | VALMARC CORP. | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237536-A1 | Treating or Preventing Pain Using Spicamycin Derivatives | OPRL1, GAP43, NTSR2 | TSHR 4546/4885THRB 4377/4885GGPS1 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.